Great day-by-day recaps of #KidneyWk from the #NephJC team—perfect if you missed a session. Begin here 👉🏻 www.nephjc.com/news/2025/11...

large cohort study of CDK 4/6 BRAF EGFR VEGF and other cancer treatments #OncoNephrology #NephSky #KidneyWk jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social

Finally, a large group of patients are those with heterozygous COL4A3 and COL4A4 variants who do well long term with only microscopic hematuria. The problem is that you don't know which patients will fall into this bucket and which will fall into the buckets above by genotyping alone. #KidneyWk

Trials coming out already! jamanetwork.com/journals/jam... Rituximab better than placebo in FRNS/SDNS Duh. #KidneyWk #NephSky

Next up Zigakibart in IgAN treated for 76 weeks. Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides) Title, methods, and table 1 demographics #GlomCon

Lionel MEST-C I'm dying #GlomCon #Edgar1ofAKind

It wouldn't be an @edgarvlermamd.bsky.social lecture without a Spiderman ref #GlomCon

Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO. He says guidelines are always backward looking. No answer about Gd-IgA1 though #GlomCon

👩🏻 75-year-old woman - History of epilepsy 📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days 🧪 Positive MPO ANCA (61.06)

After 8 years, a new AHA/ACCA hypertension guideline 📊 Proposes cardiovascular risk assessment using the PREVENT calculator. Urine albumin-to-creatinine ratio in all hypertensive patients. Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.

HDF over HD: New report from the EuDial working group More info: academic.oup.com/ndt/article/... @ndt-era.bsky.social, @hjanders.bsky.social

HiLo, HiLo it's off to work we go! ⛏️ Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️ www.nephjc.com/news/hilo-tr...

so the HiLo study was unremarkable in the treatmet of Hyperphosphahtemia, will the Phosphate trial tell us something different?

The Pathology Lesion Patterns of Podocytopathies: How and why? #ERA25 🇦🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/35281116/

Hyperkalemia rates not lower with adding a flozin to the MRA 🤔 www.nejm.org/doi/full/10.... #ERA25

The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....

www.nejm.org/doi/full/10.... Very exciting to hear about this ground breaking clinical trial at #era2025

#era25 following through social media expectorante the resultado of CONFIDENCE trial.

In Heart Failure, Finerenone 20-40mg vs placebo, ↓ cardiorenal risks, effect appears to be independient of the renal risk, ↓ albuminuria more Benefit in renal outcome PostHoc of FINEARTS-HF JACC 2025. doi.org/10.1016/j.jc...

Different guidelines hypertension targets comparisson. HYPERTENSION 2025. #Hypertension

So maybe we don’t need to hold flozins before surgery after all? jamanetwork.com/journals/jam...

📢 New CREDENCE data in NDT: SGLT2i in CKD and T2D: ✅ ↓ Insulin initiation/dose intensification by 19% ✅ ↑ Reductions in insulin dose by up to 49% ✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal academic.oup.com/ndt/advance-...

Cool picture . cats claw is quite popular in Peru. #Nephmadness 2025

Spicy! Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors @juancarlosqvelez.bsky.social doi.org/10.1016/j.ek... #nephsky #liversky

#NephMadness 2025: The PodCrawl buff.ly/p3xR3cg Podcasts: - @thecurbsiders.bsky.social - Life as a Nephrology Professional @nkf-professionals.bsky.social - GN in Ten - @rheummadness.bsky.social - @freelyfiltered.bsky.social - Poison Lab - Nephron Segment - Kidney Chronicles

Interesante

journals.lww.com/kidney360/ab.... Great paper review Kidney 360

🤔🤔Ever heard of DMANDs-Disease modifying anti nephropathic drugs doi.org/10.1093/ndt/... @hjanders.bsky.social #Nephsky #Nephpearls

✅Why is it Class 1A-1E and not class 1-5 in MIC (Mayo imaging classification)? ✅That’s because Class 1️⃣ is Typical ADPKD and Class 2️⃣ is atypical ADPKD. ✅Checkout what’s typical and atypical ADPKD 👇 ✅However, note that the predictive tool is valid for typical category only 🤔

Lifestyle interventions are the cornerstone of treatment for children with obesity, but additional treatments, such as medications, may be needed. Research findings on liraglutide in children with obesity are summarized in a Quick Take video. youtu.be/bvxWTUGVeww #MedSky #PedSky

5/ There are multiple 💊-way to reduce the P #ISNWCN But not a universal solution

3/ The source of P is also important; there animal source seems not to be associated with mortality #ISNWCN pubmed.ncbi.nlm.nih.gov/36704595/

But maybe - all the observational data is confounded? ajkdblog.org/2021/06/16/c... #ISNWCN

Current Status and Future Perspective of Onco-Hypertension #Review #OncoHypertension academic.oup.com/ajh/article/...

For HTN, starting a 2-pill low-dose Rx was noninferior to stepped monotherapy. 2-pill & 3-pill low-dose strategies were not superior to stepped monotherapy #CardioSky #MedSky jamanetwork.com/journals/jam... @jama.com @anastasiasmihaili.bsky.social @vietheartpa.bsky.social @psatishmd.bsky.social

In this article, the authors argue that it is important to increase physician awareness regarding autoantibodies-mediated tubular diseases in order to have a better estimation of the prevalence and improve patient care. bit.ly/JASN0628

Happy to announce that this is out! A flow cytometry-based quantification of urinary kidney tubular epithelial cells (TECs) as a biomarker for kidney damage in AKI and ANCA vasculitis. www.kireports.org/article/S246...

New in @natrevneph.bsky.social With Drs Blum & Grams, we explore how risk-based CKD management aligns care with risk, prioritizes absolute benefits, & improves cost-effectiveness—guiding the use of key therapies for those most likely to benefit 🔗 Read more: www.nature.com/articles/s41...

.

🔔Tweetorial Alert 🔔 1/ Hey #NephSky! Welcome to a 🆕 #skeetorial brought to you by @kireports.bsky.social

effects of iron 🩸 therapy on clinical outcomes in chronic kidney disease analyzing 45 randomized trials

accurate!!

📢 New Systematic Review & Meta-Analysis in @kireports.bsky.social 📢 We evaluated the effects of iron therapy on clinical outcomes in chronic kidney disease (CKD), analyzing 45 randomized trials. A summary of our findings: 🧵 www.kireports.org/article/S246...

Associations between initial dialysis access types and death from dialysis withdrawal in incident patients with kidney failure doi.org/10.1093/ckj/...

From my fellow

New ERA document on vitamin D use in CKD Bottom line: the use of vitamin D is to…….increase blood levels of vitamin D academic.oup.com/ndt/advance-... in @ndt-era.bsky.social #NephSky